Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

A New Poly(ADP-Ribose) Polymerase Inhibitor, FR261529 [2-(4-Chlorophenyl)-5-quinoxalinecarboxamide], Ameliorates Methamphetamine-Induced Dopaminergic Neurotoxicity in Mice

Akinori Iwashita, Kayoko Mihara, Syunji Yamazaki, Shigeru Matsuura, Junya Ishida, Hirofumi Yamamoto, Kouji Hattori, Nobuya Matsuoka and Seitaro Mutoh
Journal of Pharmacology and Experimental Therapeutics September 2004, 310 (3) 1114-1124; DOI: https://doi.org/10.1124/jpet.104.068932
Akinori Iwashita
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kayoko Mihara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Syunji Yamazaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shigeru Matsuura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junya Ishida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hirofumi Yamamoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kouji Hattori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nobuya Matsuoka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seitaro Mutoh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 310 no. 3 1114-1124
DOI 
https://doi.org/10.1124/jpet.104.068932
PubMed 
15113847

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Received March 24, 2004
  • Accepted April 27, 2004
  • Published online August 20, 2004.

Article Versions

  • Earlier version (April 27, 2004 - 12:32).
  • Earlier version (April 30, 2004 - 12:42).
  • You are viewing the most recent version of this article.
Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Akinori Iwashita,
  2. Kayoko Mihara,
  3. Syunji Yamazaki,
  4. Shigeru Matsuura,
  5. Junya Ishida,
  6. Hirofumi Yamamoto,
  7. Kouji Hattori,
  8. Nobuya Matsuoka and
  9. Seitaro Mutoh
  1. Medicinal Biology Research Laboratories (A.I., K.M., S.Y., S.M., N.M., S.M.) and Medicinal Chemistry Research Laboratories (J.I., H.Y., K.H.), Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan
  1. Address correspondence to:
    Akinori Iwashita, Department of Neuroscience, Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., 2-1-6 Kashima, Yodogawa-ku, Osaka 532-8514, Japan. E-mail: aki_iwashita{at}po.fujisawa.co.jp
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: April 2004 to March 2023

AbstractFullPdf
Apr 200424022
May 2004120085
Jun 200445058
Jul 200465048
Aug 20041584475
Sep 20041287746
Oct 2004933633
Nov 2004644927
Dec 2004462516
Jan 2005433312
Feb 200527218
Mar 2005354125
Apr 20055309
May 2005152912
Jun 2005264112
Jul 2005283511
Aug 200522275
Sep 200582111
Oct 2005131815
Nov 2005131921
Dec 2005122414
Jan 200682012
Feb 20069158
Mar 200643516
Apr 20063139
May 200612515
Jun 20064107
Jul 20067139
Aug 200652012
Sep 20065136
Oct 200691816
Nov 2006131412
Dec 2006121211
Jan 200713911
Feb 200751313
Mar 20072188
Apr 2007101220
May 200761512
Jun 200742527
Jul 200732116
Aug 200781417
Sep 2007869
Oct 200761416
Nov 20074616
Dec 2007488
Jan 2008356
Feb 20089813
Mar 2008101220
Apr 2008752
May 2008122417
Jun 20081498
Jul 20089179
Aug 20087105
Sep 20088139
Oct 200812189
Nov 2008131110
Dec 20083108
Jan 20098625
Feb 2009987
Mar 2009231312
Apr 20091159
May 20094414
Jun 2009556
Jul 200991510
Aug 20096816
Sep 2009789
Oct 200912810
Nov 20095816
Dec 20096118
Jan 20106209
Feb 2010936
Mar 2010865
Apr 2010131
May 2010656
Jun 2010869
Jul 2010246
Aug 2010392
Sep 2010668
Oct 20103155
Nov 20108104
Dec 2010682
Jan 2011675
Feb 20114810
Mar 201171116
Apr 20115510
May 201161915
Jun 2011767
Jul 201113106
Aug 201110169
Sep 20119189
Oct 20114114
Nov 201118127
Dec 201181418
Jan 2012101010
Feb 201211914
Mar 20126169
Apr 20129610
May 201211710
Jun 20127610
Jul 20121057
Aug 201211137
Sep 2012955
Oct 20128146
Nov 2012986
Dec 201271310
Jan 20136158
Feb 2013843
Mar 20138910
Apr 201310312
May 2013201817
Jun 20131199
Jul 2013235
Aug 2013656
Sep 20131649
Oct 2013481
Nov 20137104
Dec 2013336
Jan 2014121113
Feb 2014312
Mar 2014852
Apr 20141065
May 201413146
Jun 2014943
Jul 20142486
Aug 2014422
Sep 2014785
Oct 2014995
Nov 2014431
Dec 2014201
Jan 2015744
Feb 2015115
Mar 2015533
Apr 2015654
May 2015662
Jun 20154510
Jul 2015627
Aug 2015273
Sep 20151234
Oct 2015277
Nov 2015562
Dec 2015513
Jan 2016517
Feb 20161028
Mar 20168714
Apr 20167311
May 20163410
Jun 2016646
Jul 20165610
Aug 20161717
Sep 201614519
Oct 20168138
Nov 2016656
Dec 2016013
Jan 2017065
Feb 2017145
Mar 2017086
Apr 2017184
May 2017123
Jun 2017040
Jul 2017134
Aug 2017031
Sep 20171610
Oct 2017377
Nov 20171178
Dec 2017240
Jan 20180123
Feb 20181123
Mar 2018267
Apr 2018087
May 2018273
Jun 2018075
Jul 2018055
Aug 2018370
Sep 2018044
Oct 201831615
Nov 20180828
Dec 20181461
Jan 20191811
Feb 20192711
Mar 20192124
Apr 20191213
May 2019725
Jun 2019907
Jul 20192010
Aug 2019501
Sep 20191813
Oct 2019701
Nov 20191700
Dec 20191402
Jan 20201501
Feb 20201143
Mar 20201600
Apr 20201712
May 2020601
Jun 20201611
Jul 2020801
Aug 2020505
Sep 20201400
Oct 20201400
Nov 20201301
Dec 20202311
Jan 20211242
Feb 2021752
Mar 20211222
Apr 20211211
May 2021933
Jun 20211120
Jul 20211323
Aug 2021732
Sep 2021910
Oct 20212111
Nov 2021810
Dec 20211206
Jan 202211112
Feb 20221012
Mar 2022921
Apr 20221218
May 2022923
Jun 20221110
Jul 20221622
Aug 20222727
Sep 20224716
Oct 2022610
Nov 20221510
Dec 20221410
Jan 20232324
Feb 2023731
Mar 20231600

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 310 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 310, Issue 3
1 Sep 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A New Poly(ADP-Ribose) Polymerase Inhibitor, FR261529 [2-(4-Chlorophenyl)-5-quinoxalinecarboxamide], Ameliorates Methamphetamine-Induced Dopaminergic Neurotoxicity in Mice
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

A New Poly(ADP-Ribose) Polymerase Inhibitor, FR261529 [2-(4-Chlorophenyl)-5-quinoxalinecarboxamide], Ameliorates Methamphetamine-Induced Dopaminergic Neurotoxicity in Mice

Akinori Iwashita, Kayoko Mihara, Syunji Yamazaki, Shigeru Matsuura, Junya Ishida, Hirofumi Yamamoto, Kouji Hattori, Nobuya Matsuoka and Seitaro Mutoh
Journal of Pharmacology and Experimental Therapeutics September 1, 2004, 310 (3) 1114-1124; DOI: https://doi.org/10.1124/jpet.104.068932

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

A New Poly(ADP-Ribose) Polymerase Inhibitor, FR261529 [2-(4-Chlorophenyl)-5-quinoxalinecarboxamide], Ameliorates Methamphetamine-Induced Dopaminergic Neurotoxicity in Mice

Akinori Iwashita, Kayoko Mihara, Syunji Yamazaki, Shigeru Matsuura, Junya Ishida, Hirofumi Yamamoto, Kouji Hattori, Nobuya Matsuoka and Seitaro Mutoh
Journal of Pharmacology and Experimental Therapeutics September 1, 2004, 310 (3) 1114-1124; DOI: https://doi.org/10.1124/jpet.104.068932
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Substituted Tryptamine Activity at 5-HT Receptors and SERT
  • KRM-II-81 Analogs
  • VTA muscarinic M5 receptors and effort-choice behavior
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics